Salivary and Serum B-cell Activating Factor (BAFF) Levels after Hydroxychloroquine Treatment in Primary Sjogren's Syndrome


Mumcu G. , Bicakcigil M., Yilmaz N., Ozay H., Karacayli U., Cimilli H. , et al.

ORAL HEALTH & PREVENTIVE DENTISTRY, cilt.11, ss.229-234, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 11 Konu: 3
  • Basım Tarihi: 2013
  • Doi Numarası: 10.3290/j.ohpd.a30172
  • Dergi Adı: ORAL HEALTH & PREVENTIVE DENTISTRY
  • Sayfa Sayısı: ss.229-234

Özet

Purpose: Some evidence implicates a role of hydroxychloroquine (HQ) in the management of Sjogren's syndrome. This study evaluated the effect of HQ on saliva B-cell activating factor (BAFF) levels as well as health related quality of life (QoL) in patients with primary Sjogren's syndrome (pSS).